

ORIGINAL RESEARCH

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe

A Judd,¹ R Lodwick,² A Noguera-Julian,^{3,4,5} DM Gibb,¹ K Butler,⁶ D Costagliola,⁷ C Sabin,² A van Sighem,⁸ B Ledergerber,⁹ C Torti,¹⁰ A Mocroft,² D Podzamczar,¹¹ M Dorrucchi,¹² S De Wit,¹³ N Obel,¹⁴ F Dabis,^{15,16} A Cozzi-Lepri,² F García,¹⁷ NH Brockmeyer,¹⁸ J Warszawski,¹⁹ MI Gonzalez-Tome,²⁰ C Mussini,²¹ G Touloumi,²² R Zangerle,²³ J Ghosn,^{24,25} A Castagna,²⁶ G Fätkenheuer,²⁷ C Stephan,²⁸ L Meyer,^{29,30} MA Campbell,³¹ G Chene^{15,16,32} and A Phillips² The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

¹MRC Clinical Trials Unit, University College London, London, UK, ²Department of Infection and Population Health, University College London, London, UK, ³Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain, ⁵CIBER de Epidemiología y Salud Pública Ciberesp, Barcelona, Spain, ⁶Department of Infectious Diseases and Immunology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland, ⁷INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Sorbonne Universités, Paris, France, ⁸Stichting HIV Monitoring, Amsterdam, The Netherlands, ⁹Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland, ¹⁰Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy, ¹¹HIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge. L'Hospitalet, Barcelona, Spain, ¹²Istituto Superiore di Sanità, Rome, Italy, ¹³Département of Infectious Diseases, Centre Hospitalier Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium, ¹⁴Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ¹⁵INSERM U1219 – Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France, ¹⁶ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France, ¹⁷Clinical Microbiology Department, Complejo Hospitalario Universitario Granada, Instituto de Investigación Biosanitaria IBS.Granada, Granada, Spain, ¹⁸Department of Dermatology, Venerology and Allergology, Center for Sexual Health and Medicine, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany, ¹⁹INSERM CESP U1018, AP-HP Public Health Department, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre Paris, France, ²⁰HIV and Paeds Infectious Diseases Department, Hospital 12 de Octubre, Madrid, Spain, ²¹Infectious Diseases Clinics, University Hospital, Modena, Italy, ²²Department Hygiene, Epidemiology & Medical Statistics, Medical School, National & Kapodistrian University of Athens, Athens, Greece, ²³Medical University Innsbruck, Innsbruck, Austria, ²⁴EA 7327, Faculté de Médecine site Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ²⁵APHP, Unité Fonctionnelle de Thérapeutique en Immuno-Infectiologie, Hôpitaux Universitaires Paris Centre site Hôtel Dieu, Paris, France, ²⁶San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy, ²⁷Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany, ²⁸Second Medical Department, Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, Germany, ²⁹INSERM CESP U1018, Université Paris-Sud, Université Paris-Saclay, Paris, France, ³⁰AP-HP Public Health Department, Le Kremlin-Bicêtre, Paris, France, ³¹Centre for Health and Infectious Disease Research, University of Copenhagen, Copenhagen, Denmark and ³²CHU de Bordeaux, Pole de sante publique, Service d'information medicale, Bordeaux, France

Correspondence: Dr Ali Judd, MRC Clinical Trials Unit, University College London, 125 Kingsway, London WC2B 6NH, UK. Tel: +44 20 7670 4830; fax: +44 20 7670 4690; e-mail: a.judd@ucl.ac.uk

*See Appendices 1 and 2.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Objectives

The aim of the study was to determine the time to, and risk factors for, triple-class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection.

Methods

We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15–29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500 HIV-1 RNA copies/mL despite \geq 4 months of use. TCVF was defined as cumulative failure of two NRTIs, an NNRTI and a bPI.

Results

The median number of weeks between diagnosis and the start of ART was higher in participants with perinatal HIV infection compared with participants with heterosexually acquired HIV infection overall [17 (interquartile range (IQR) 4–111) *vs.* 8 (IQR 2–38) weeks, respectively], and highest in perinatally infected participants aged 10–14 years [49 (IQR 9–267) weeks]. The cumulative proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.0–12.3%] in participants with perinatally acquired infection and 4.7% (95% CI 3.9–5.5%) in participants with heterosexually acquired infection, and highest in perinatally infected participants aged 10–14 years when starting ART (27.7%; 95% CI 13.2–42.1%). Across all participants, significant predictors of TCVF were those with perinatal HIV aged 10–14 years, African origin, pre-ART AIDS, NNRTI-based initial regimens, higher pre-ART viral load and lower pre-ART CD4.

Conclusions

The results suggest a beneficial effect of starting ART before adolescence, and starting young people on boosted PIs, to maximize treatment response during this transitional stage of development.

Keywords: Europe, perinatal HIV infection, virological failure, young people.

Accepted 4 April 2016

Introduction

One of the major challenges for children and young people with perinatal HIV infection is the maintenance of long-term adherence to treatment regimens to suppress virus and prevent resistant virus from developing [1]. Paediatric HIV treatment regimens have relied heavily on drugs from one or more of the original three antiretroviral therapy (ART) classes [nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), and boosted protease inhibitors (bPIs)], as drugs from newer classes often lack paediatric pharmacokinetic data and are not approved for use in children (e.g. rilpivirine, elvitegravir in <18 years of age, dolutegravir in < 12 years of age), or do not have appropriate paediatric formulations, and are often expensive [2].

Current European guidelines recommend initiation of treatment in all infants aged < 1 year, in children

\geq 1 year of age according to age-specific immunological thresholds (1–3 years, CD4 count \leq 1000 cells/ μ L or CD4% \leq 25%; 3–5 years, CD4 count \leq 750 cells/ μ L or CD4% \leq 25%; >5 years, CD4 count \leq 350 cells/ μ L), and in any child with a World Health Organization (WHO) stage 3/4 or Centers for Disease Control and Prevention (CDC) category B/C event, largely to prevent progression to AIDS and death and to potentially optimize the ultimate CD4 count in adulthood [3]. In a previous study, we showed how the risk of triple-class virological failure (TCVF) of the three original drug classes in children also increased with older age at the start of ART [4]. However, the main analysis of that study used a broad definition of TCVF which included now outdated treatment regimens, including unboosted PIs. A restricted analysis (including two NRTIs with either an NNRTI or a bPI) suggested that the overall rate of failure in children was over twice as high as in adults with heterosexually acquired HIV

infection (hazard ratio 2.2; 95% confidence interval (CI) 1.6, 3.0; $P < 0.0001$). Here we further explored the difference in TCVF rates between perinatally infected children and young adults aged 15 to 29 years with heterosexual infection, and in particular looked at the effect of age at the start of ART on risk of TCVF.

Methods

Data were pooled from 22 cohort studies participating in the Pursuing Later Treatment Options II (PLATO II) project in 2010, which is part of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord (www.cohere.org and www.eurocoord.net), a collaboration of European cohort studies [5]. This study included 22 cohort studies with data on heterosexually infected adults aged 15–29 years, and five cohort studies with paediatric data on perinatally infected children and young people aged < 20 years. We chose these age groups as we wished to compare perinatally HIV-infected children and teenagers with adults with horizontal infection who were of a similar age group, and to show how the risk of TCVF differs across this age spectrum. A comparison of younger and older age groups has already been published elsewhere [6]. The cohort studies included diagnosed HIV-infected patients attending treatment services across Europe, collecting similar data items. Data submission and quality control procedures have been described previously [5].

Participants were antiretroviral-naïve or had previous ART exposure for prevention of mother-to-child transmission (PMTCT), and started ART from 1998 onwards with an initial regimen of two or more NRTIs and either an NNRTI or a bPI. Follow-up time began at the start of ART and data were censored at the last reported viral load measurement. Because the definition of virological failure used in this study required 4 months of use of a drug, children were only included if they had at least 4 months (122 days) of follow-up. Time spent off ART (after ART had been started) was included as follow-up. Participants were said to be off ART if they stopped all antiretroviral drugs. Treatment interruption was defined as cessation of all antiretrovirals for at least 7 days.

The main outcome measure was time to TCVF, defined as virological failure of at least two NRTI drugs, one NNRTI drug, and one bPI drug. Virological failure of a drug was defined as one viral load > 500 HIV-1 RNA copies/mL following at least 4 months of continuous use of that drug, regardless of concomitant use of other drugs in that period. Sensitivity analyses were conducted using two variations of this virological failure definition: first, 6 months instead of 4 months of continuous drug use;

secondly, viral load > 500 copies/mL after 4 months of continuous use had to be confirmed by a second viral load > 500 copies/mL while still on the drug or followed by discontinuation of the drug.

The date of the first HIV clinic visit was calculated as the earliest date of: first CD4 count, first viral load measurement, first visit, first diagnosis of an AIDS-defining condition, or start of ART (including ART for PMTCT).

Kaplan–Meier and Cox regression methods were used to investigate the risk of TCVF after starting ART. Potential predictors of TCVF at the time of starting ART were sex, age group/risk group, region of origin, year of starting ART, initial regimen, previous ART exposure for PMTCT, pre-ART AIDS diagnosis, CD4 (a binary measure combining CD4% $\leq 25\%$ for patients < 5 years of age and CD4 count ≤ 350 cells/ μL for patients ≥ 5 years of age), and viral load (a binary measure, above or below the median viral load within each age group). In multi-variable analyses, perinatally HIV-infected young people aged 15–19 years at the start of ART were excluded because of their small number ($n = 20$) and lack of TCVF events. HIV-related outcomes for those experiencing TCVF are described.

Analyses were performed using SAS software, version 9.3 (SAS Inc., Cary, NC).

Results

A total of 5972 participants fulfilling the inclusion criteria were identified, and their characteristics at the start of ART by risk group and age are summarized in Table 1. Overall, 806 participants (13%) had perinatally acquired HIV infection, and started ART aged < 20 years, and 5166 participants (87%) acquired HIV heterosexually and started ART aged 15–29 years. In the 15–19 years age category, 20 (7%) had perinatally acquired HIV infection and 264 (93%) had heterosexually acquired HIV infection, while all those < 15 years of age had perinatally acquired HIV infection, and all those ≥ 20 years of age had acquired HIV heterosexually. Initial regimens included lopinavir/r for 26% of participants with heterosexually acquired HIV infection and 17% of those with perinatally acquired HIV infection, efavirenz for 34% of those with heterosexually acquired HIV infection and 37% of those with perinatally acquired HIV infection, and nevirapine for 26% of those with heterosexually acquired HIV infection and 46% of those with perinatally acquired HIV infection.

Around half of participants with perinatally acquired HIV infection and three-quarters of those with heterosexually acquired HIV infection were female, and the majority of most age groups were from sub-Saharan Africa. In

Table 1 Characteristics of the 5972 included participants at the start of antiretroviral therapy (ART)

Characteristic	Risk group							
	Perinatal				Heterosexual			
	Age at start of ART (years)							
	< 2	2–4	5–9	10–14	15–19	15–19	20–24	25–29
Number (%) of participants	238 (4)	148 (2)	229 (4)	171 (3)	20 (<1)	264 (4)	1459 (24)	3443 (58)
Sex [n (%)]								
Male	101 (42)	83 (56)	119 (52)	79 (46)	6 (30)	58 (22)	319 (22)	946 (27)
Female	137 (58)	65 (44)	110 (48)	92 (54)	14 (70)	206 (78)	1140 (78)	2497 (73)
Region of origin [n (%)]								
Sub-Saharan Africa	57 (24)	75 (51)	153 (67)	112 (65)	15 (75)	103 (39)	459 (31)	902 (26)
Europe	169 (71)	61 (41)	62 (27)	50 (29)	5 (25)	35 (13)	277 (19)	708 (21)
Other	11 (5)	12 (8)	13 (6)	8 (5)	0 (0)	6 (10)	195 (13)	536 (16)
Unknown	1 (<1)	0 (0)	1 (<1)	1 (1)	0 (0)	100 (38)	528 (36)	1297 (38)
Pre-ART AIDS [n (%)]								
Yes	69 (29)	27 (18)	30 (13)	21 (12)	1 (5)	38 (14)	174 (12)	501 (15)
Time from diagnosis to ART start (weeks) [median (IQR)]	6 (2–18)	24 (5–102)	41 (5–185)	49 (9–267)	176 (55–404)	6 (1–19)	7 (2–33)	8 (2–44)
CD4 count								
Median (IQR) (cells/ μ L)	1170 (490–1818)	510 (279–793)	281 (160–482)	190 (94–286)	181 (89–231)	262 (163–395)	252 (155–375)	226 (125–325)
Missing [n (%)]	79 (33)	21 (14)	41 (18)	28 (16)	4 (20)	38 (14)	199 (14)	466 (14)
CD4 percentage								
Median (IQR)	25 (15–33)	14 (10–19)	13 (9–18)	12 (6–17)	–	–	–	–
Missing [n (%)]	81 (34)	20 (14)	48 (21)	31 (18)				
Viral load								
Median (IQR) (\log_{10} copies/mL)	5.7 (5.0–5.9)	5.1 (4.7–5.6)	5.0 (4.6–5.3)	4.8 (4.2–5.2)	4.5 (4.2–4.8)	4.8 (3.9–5.2)	4.6 (4.0–5.0)	4.6 (4.0–5.1)
Missing [n (%)]	67 (28)	19 (13)	49 (21)	25 (15)	2 (10)	44 (17)	208 (14)	509 (15)
Year of starting ART [n (%)]								
1998–2000	43 (18)	31 (21)	28 (12)	15 (9)	2 (10)	33 (13)	232 (16)	565 (16)
2001–2003	81 (34)	51 (34)	81 (35)	43 (25)	1 (5)	90 (34)	416 (29)	1018 (30)
2004–2006	79 (33)	48 (32)	91 (40)	74 (43)	9 (45)	106 (40)	548 (38)	1261 (37)
2007–2009	35 (15)	18 (12)	29 (13)	39 (23)	8 (40)	35 (13)	263 (18)	599 (17)
Initial regimen [n (%)]								
NNRTI + ≥ 2 NRTIs	175 (74)	126 (85)	200 (87)	150 (88)	15 (75)	150 (57)	833 (57)	2107 (61)
bPI + ≥ 2 NRTIs	63 (26)	22 (15)	29 (13)	21 (12)	5 (25)	114 (43)	626 (43)	1336 (39)
PMTCT [n (%)]								
Yes	53 (22)	7 (5)	1 (< 1)	–	–	–	–	–

bPI, boosted protease inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PMTCT, prevention of mother-to-child transmission.

participants with perinatal HIV infection, the median age when first seen was 0.5 years [interquartile range (IQR) 0.0–2.7 years] for those born in Europe compared with 5.9 years (IQR 2.4–9.4 years) for those from sub-Saharan Africa. The median duration between date first seen and the start of ART varied by risk group and age. It was around 6–8 weeks for infants with perinatal HIV infection and participants who acquired HIV infection heterosexually, but much longer for children with perinatal HIV infection starting ART at age 5–9 years and 10–14 years [median 41 (IQR 5–185) and 49 (IQR 9–267) weeks,

respectively], and highest in participants with perinatal HIV infection starting ART at age 15–19 years, although numbers were small [median 176 (IQR 55–404); $n = 20$] (Table S1).

Median CD4 cell count at the start of ART was lower in participants with perinatal HIV infection aged 10–14 and 15–19 years than in participants who acquired HIV heterosexually and also younger patients with perinatal HIV infection, and, as expected, the median CD4 percentage was higher in infants than in other perinatally infected groups. Similarly, viral load was highest in

perinatally infected infants, and lowest at around 4.6 log₁₀ copies/mL in all patients aged ≥ 10 years. Most participants started ART between 2000 and 2006. The vast majority (83%) of patients with perinatal HIV infection and 60% of those who acquired HIV heterosexually started on an NNRTI-based regimen.

The overall median follow-up from the start of ART was 3.5 (IQR 1.7–5.9) years. The median duration of follow-up was markedly lower for participants with perinatal HIV infection aged 15–19 years [1.4 (IQR 1.0–2.3) years]. The rate (95% CI) of treatment interruption was 7.4 (6.5–8.4) per 100 person-years in participants with perinatal HIV infection and 9.8 (9.4–10.3) per 100 person-years in adults who had acquired HIV heterosexually. In those who had interrupted treatment, the rate (95% CI) of restarting was 67.4 (57.2–78.9) per 100 person-years in participants with perinatal HIV infection and 56.4 (53.5–59.5) per 100 person-years in those with heterosexually acquired HIV.

Just under half (357) of participants with perinatal HIV infection and 1774 of those who acquired HIV heterosexually experienced virological failure. By 5 years after starting ART, 49.9% (95% CI 45.8–54.0%) and 41.2% (95% CI 39.5–42.8%), respectively, had experienced virological failure, with no marked differences by age group (Table S1). By the end of follow-up, 216 of 806 patients with perinatal HIV infection and 1539 of 5166 patients with heterosexually acquired HIV had started a third drug class, and 70 with perinatal HIV infection and 182 with heterosexually acquired HIV had developed TCVF. The cumulative proportion of participants experiencing TCVF by age at the start of ART and risk group is shown in Table 2 and Figure 1, and was higher in patients with perinatal HIV infection compared with those with heterosexually acquired HIV overall, and was particularly high in perinatally infected participants aged 10–14 years, at 27.7% (95% CI 13.2–42.1) by 5 years (Table S1). Of the 252 patients overall with TCVF, 12 (4.8%) had never attained a viral load ≤ 500 copies/mL.

In a multivariable model (Table 2), after adjustment for other factors, there was a strong association between age group and risk group and risk of TCVF. Participants with perinatal HIV infection aged 10–14 years at ART initiation had a markedly raised risk of failure [hazard ratio (HR) 5.19; 95% CI 3.11–8.65], participants with perinatal HIV infection aged < 10 years had an increased risk (e.g. 5–9 years: HR 1.96; 95% CI 1.18–3.25), and those with heterosexually acquired HIV aged 15–19 years (HR 0.76; 95% CI 0.36–1.65) and 20–24 years (HR 1.36; 95% CI 0.99–1.85) had a similar risk, compared with those with heterosexually acquired HIV infection aged 25–29 years. Additionally, participants originating from Europe

compared with sub-Saharan Africa and those starting bPI regimens compared with NNRTI regimens had a lower risk, and those with an AIDS diagnosis before starting ART had a higher risk, as did those with a higher pre-ART viral load and lower pre-ART CD4. There was no difference in the risk of failure by sex, ART exposure for PMTCT in infancy, or year of ART initiation. Sensitivity analyses conducted using two variations of the virological failure definition produced similar results, including in patients < 2 years of age with perinatal infection.

Clinical outcomes following TCVF are shown in Table S2. Overall, 1 year after TCVF, CD4 counts were higher in younger participants with perinatally acquired HIV infection and those with heterosexually acquired HIV infection than in participants with perinatal HIV infection aged 10–14 years, although numbers were small. Similarly, median viral load was higher in perinatally infected participants aged 10–14 years and lower in all other participant groups. Five per cent (three of 64) of participants with perinatal HIV infection with follow-up data available after TCVF had been diagnosed with AIDS or died, compared with 11% (19 of 170) of participants with heterosexually acquired HIV infection; 9% (six of 64) of perinatally infected participants compared with 25% (43 of 170) of those with heterosexually acquired HIV infection had started at least one new drug by 1 year following TCVF.

Discussion

In this large collaborative study in which the risk of TCVF from the start of ART in perinatally HIV-infected children was directly compared with that in adults with heterosexually acquired HIV infection, 4.2% developed TCVF overall. The highest risk of TCVF was in 10–14-year-old participants with perinatal infection; for this group, the cumulative incidence of TCVF by 3 years was nearly 10%, rising sharply to just under 30% by 5 years, while in all other age groups the proportion at 5 years was < 9%. This trend was shown in the multivariable analysis in which the rate of failure in this group was five times higher than in adults aged 25–29 years with heterosexually transmitted HIV infection. These results augment those of our earlier study which described the rate and predictors of TCVF in children, and which presented only a very simple analysis comparing rates between children and adults [4]. Here, we estimated the differing rates of TCVF across the age spectrum from infants to young adults, as well as by transmission group.

Participants with perinatally acquired HIV infection aged 10–14 years had not only the highest rate of TCVF but also the longest delay in starting ART following HIV

Table 2 Participants developing triple-class virological failure (TCVF): number, proportion, and predictors from univariable and multivariable Cox models

	Estimated cumulative proportion developing TCVF by 5 years (%) [†]	Univariable results			Multivariable results		
		HR	95% CI	P-value	HR	95% CI	P-value
Sex							
Male	6.9 (5.2–8.5)	1	–	0.0055	1	–	0.17
Female	4.9 (3.9–5.8)	0.70	0.54–0.90		0.83	0.64–1.09	
Age at start of ART and risk group							
< 2 years; perinatally acquired	7.8 (3.7–12.0)	1.83	1.11–3.00	<0.0001	2.16	1.25–3.72	<0.0001
2–4 years; perinatally acquired	4.5 (0.6–8.5)	1.67	0.90–3.09		1.45	0.76–2.75	
5–9 years; perinatally acquired	8.4 (3.9–12.9)	2.49	1.56–3.96		1.96	1.18–3.25	
10–14 years; perinatally acquired	27.7 (13.2–42.1)	6.16	3.81–9.97		5.19	3.11–8.65	
15–19 years; heterosexually acquired*	2.1 (0.0–4.1)	0.84	0.39–1.80		0.76	0.36–1.65	
20–24 years; heterosexually acquired	5.8 (4.0–7.6)	1.34	0.98–1.82		1.36	0.99–1.85	
25–29 years; heterosexually acquired	4.5 (3.5–5.4)	1	–		1	–	
Region of origin							
Sub-Saharan Africa	6.8 (5.2–8.5)	1	–	0.0003	1	–	0.012
Europe	4.5 (3.0–6.0)	0.56	0.40–0.79		0.59	0.41–0.84	
Other/unknown	5.1 (3.9–6.3)	0.61	0.46–0.81		0.79	0.58–1.08	
Pre-ART AIDS							
No	4.9 (4.0–5.7)	1	–	0.0044	1	–	0.039
Yes	8.5 (6.1–11.0)	1.55	1.15–2.08		1.38	1.02–1.88	
Initial regimen							
NNRTI + ≥2 NRTIs	6.1 (5.1–7.1)	1	–	0.0011	1	–	0.0023
bPI + ≥2 NRTIs	3.9 (2.5–5.3)	0.58	0.42–0.80		0.59	0.42–0.83	
Pre-ART CD4 composite measure [‡]							
CD4% < 25%/CD4 < 350 cells/μL	6.3 (5.2–7.4)	1	–	0.044	1	–	0.009
CD4% ≥ 25%/CD4 ≥ 350 cells/μL	3.8 (2.3–5.3)	0.74	0.53–1.03		0.85	0.60–1.20	
Unknown	4.4 (2.6–6.1)	0.68	0.47–0.99		0.48	0.29–0.77	
Pre-ART viral load							
Below median for age group	3.3 (2.3–4.3)	1	–	0.0018	1	–	0.0005
Above median for age group	7.0 (5.6–8.3)	1.67	1.26–2.22		1.66	1.24–2.22	
Unknown	6.6 (4.4–8.7)	1.47	1.01–2.14		2.13	1.34–3.40	

ART, antiretroviral therapy; bPI, boosted protease inhibitor; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.

Year of starting ART (unadjusted $P = 0.43$), previous ART exposure for prevention of mother-to-child transmission (unadjusted $P = 0.083$) and sex (adjusted $P = 0.09$) were all not significant.

*For the age group 15–19 years, data are shown for participants with heterosexually acquired HIV infection only, as there were only 20 participants and no events in the 15–19-year age group for participants with perinatally acquired HIV infection.

[†]Kaplan–Meier estimates (95% confidence intervals).

[‡]CD4% for < 5 years; CD4 count for ≥ 5 years.

diagnosis, and the lowest CD4 counts at the start of ART. Many of these young people were born in sub-Saharan Africa, some without access to antenatal testing; they may have complex family issues with a high proportion being orphans, and HIV symptoms may not have been recognized, leading to delayed diagnosis [7,8]. Some will have insecure immigration status which can intensify concerns about HIV diagnosis and treatment, and disclosure of HIV infection in the family [9,10]. There can also be issues of coming to terms with their own HIV status, secrecy and guilt among other family members, and dealing with HIV infection in the context of the adolescent transitional stage of development [11,12]. Once ART has been started, studies have found lower rates of viral suppression in young people with perinatal HIV infection compared with adults [13], which are probably attributable to adherence issues and poor clinic attendance rather

than drug efficacy, both common problems among young adults living with other chronic diseases [1, 14–16]. Findings from this study support the benefit of earlier age at diagnosis where possible, and initiation of ART prior to the adolescent period, which will probably also favour improved immunological health [17].

In this study, most participants with perinatal HIV infection started on an NNRTI-based regimen, while two-fifths of participants with heterosexually acquired infection in the study started on bPIs, and those starting with bPI-based regimens were less likely to develop TCVF. In our previous study with resistance test data, we found that most children on an NNRTI regimen had resistance mutations, but PI resistance was not seen [4]. Resistance results from the PENPACT-1 trial showed that delaying switching for those starting a PI-based regimen was a reasonable strategy, but that more rapid switching from




Fig. 1 Kaplan–Meier plots showing the cumulative proportion of participants experiencing triple-class virological failure (TCVF) by age at the start of antiretroviral therapy (ART) and risk group.

an NNRTI-based regimen following virological failure was needed to avoid accumulation of NRTI resistance mutations [18]; in this study, these findings would mean that a higher proportion of the NNRTI group would be at risk of TCVF. However, results from a large adult trial of second-line treatment following NNRTI-based first-line therapy suggested that participants given a PI as second-line therapy retained NRTI virological activity without evidence of increased toxicity, even in the presence of NRTI resistance mutations [19], suggesting that, although in our study participants met the criteria of TCVF, its impact may not be substantial.

European guidelines now recommend that if adherence is questionable, as is often seen in teenagers, a PI-based regimen should be initiated because of its higher genetic barrier to resistance [3,20]. Many of the participants with perinatal HIV infection on PI-based regimens in our study would have been on lopinavir/r regimens, which are unpopular among adolescents as they require twice-daily administration, but now both darunavir and atazanavir are available to adolescents in once-daily formulations and have better tolerability. Furthermore, two new once-daily single-tablet regimens combining integrase inhibitors with an NRTI backbone have recently been licensed for adults and children aged 12 years and older weighing at least 35–40 kg and may become a suitable alternative to PI-based regimens for adolescents [21–25]. Similarly, innovative treatment strategies designed to improve adherence are needed for adolescents, and the phase II

BREAKs in Adolescent and child Therapy using Efavirenz and two nRTIs (BREATHER) trial recently reported non-inferiority of virological suppression in young people on efavirenz plus two NRTIs having weekends off compared with continuous therapy; long-term follow-up of these trial participants has begun [26].

In conclusion, for participants with perinatal HIV infection, these findings indicate the need to diagnose and start ART earlier in childhood, and adopt a strategic approach in ART selection to prevent the emergence of resistance. These measures may help children and adolescents achieve and sustain virological suppression as they approach adulthood.

Conflict of interest

B Ledergerber has received travel grants, grants or honoraria from Janssen, Gilead and ViiV. A Mocroft has received honoraria, consultancy fees, travel support and/or lecture fees from Gilead, BMS, Pfizer, Merck, BI and Wragge LLC. A Phillips has received consultancy/ payment for lectures from Gilead, GSK Biologicals, Abbvie. D Costagliola was a member of the French Gilead HIV board up to 2015. In the past 3 years she gave lectures for Janssen-Cilag, Merck-Sharp & Dohme-Chibret, ViiV and received travel/accommodations/meeting expenses from Gilead, ViiV, Janssen-Cilag. She conducted post-marketing studies for Janssen-Cilag, Merck-Sharp & Dohme-Chibret and ViiV. She is currently a consultant of

Innavirvax. Norbert H. Brockmeyer received grants and travel/accommodations/meeting expenses from Gilead, Sanofi Pasteur, Roche, AbbVie, BMS and Janssen Cilag, and payments to his institution for consultancy and development of educational presentations from Gilead and for consultancy for MSD. Maria Isabel Gonzalez-Tome has received Gilead fellowship 2014 and has collaborated in clinical trials (Gilead, Pfizer.)

Acknowledgements

Financial disclosure: The PLATO II project is funded by the UK Medical Research Council (award G0700832). The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; the HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement no 260694. The group has also received project-specific funding from the UK Medical Research Council and the Swiss Bridge Foundation. A list of the funders of the participating cohorts can be found at www.COHERE.org. The funding sources had no role in the study design, the collection, analysis and interpretation of data, the writing of the report or the decision to submit the paper for publication.

Author contributions

All members of the PLATO II Writing Group participated in discussions on the design of the study, the choice of statistical analyses and interpretation of the findings, and were involved in the preparation and review of the final manuscript for submission. In addition, Rebecca Lodwick and Andrew Phillips were responsible for performing all analyses; Dr Lodwick acts as guarantor for the analyses and has full access to the data set. Study concept and design: A. Judd, R. Lodwick, A. Noguera-Julian, D. M. Gibb, K. Butler and A. Phillips. Acquisition of data: A. Judd, A. Noguera-Julian, D. M. Gibb, K. Butler, D. Costagliola, C. Sabin, A. van Sighem, B. Ledergerber, C. Torti, A. Mocroft, D. Podzamczar, M. Dorrucchi, S. De Wit, N. Obel, F. Dabis, A. Cozzi-Lepri, F. García, N. Brockmeyer, J. Warszawski, M. Gonzalez-Tome, C. Mussini, G. Touloumi, R. Zangerle, J. Ghosn, A. Castagna, G. Fätkenheuer, C. Stephan, L. Meyer, M. A. Campbell, G. Chene and A. Phillips. Analysis and interpretation of data: A. Judd, R. Lodwick, M. Gonzalez-Tome, A. Noguera-Julian, D. M. Gibb, K. Butler and A. Phillips. Drafting of the

manuscript: A. Judd, R. Lodwick, D. M. Gibb and A. Phillips. Critical revision of the manuscript for important intellectual content: all authors.

References

- 1 Mofenson LM, Cotton MF. The challenges of success: adolescents with perinatal HIV infection. *J Int AIDS Soc* 2013; **16**: 18650.
- 2 Turkova A, Webb RH, Lyall H. When to start, what to start and other treatment controversies in pediatric HIV infection. *Paediatr Drugs* 2012; **14**: 361–376.
- 3 Bamford A, Turkova A, Lyall H *et al.* Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. *HIV Med* 2015. doi: 10.1111/hiv.12217. [Epub ahead of print].
- 4 The Pursuing Later Treatment Options II. (PLATO II) project team. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* 2011; **377**: 1580–1587.
- 5 Collaboration of Observational HIV Epidemiological Research Europe. (COHERE) study group. Response to combination antiretroviral therapy: variation by age. *AIDS* 2008; **22**: 1463–1473.
- 6 Pursuing Later Treatment Options II. (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010; **170**: 410–419.
- 7 Judd A, Nunn A, Melvin D *et al.*, editors. Neurocognitive function in perinatally HIV-infected young people and HIV-negative siblings in England. 21st Annual Conference of the British HIV Association; 2015; Brighton, UK.
- 8 Judd A, Ferrand R, Jungmann E *et al.* Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. *HIV Med* 2009; **10**: 253–256.
- 9 Conway M. *Children, HIV, asylum and immigration*. London, National Children's Bureau, 2006.
- 10 British HIV Association. *Don't Forget the Children. Guidance for the HIV TESTING of Children with HIV-Positive Parents*. London, Mediscript Ltd, 2009.
- 11 Fegran L, Hall EO, Uhrenfeldt L, Aagaard H, Ludvigsen MS. Adolescents' and young adults' transition experiences when transferring from paediatric to adult care: a qualitative metasynthesis. *Int J Nurs Stud* 2014; **51**: 123–135.
- 12 Newman C, Persson A, Miller A, Cama E. Bridging worlds, breaking rules: clinician perspectives on transitioning young people with perinatally acquired HIV into adult care in a low

- prevalence setting. *AIDS Patient Care STDS* 2014; **28**: 381–393.
- 13 Dollfus C, Le Chenadec J, Faye A *et al.* Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). *Clin Infect Dis* 2010; **51**: 214–224.
 - 14 Rice BD, Delpuch VC, Chadborn TR, Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. *Sex Transm Dis* 2011; **38**: 685–690.
 - 15 Fleming E, Carter B, Gillibrand W. The transition of adolescents with diabetes from the children's health care service into the adult health care service: a review of the literature. *J Clin Nurs* 2002; **11**: 560–567.
 - 16 Rianthavorn P, Ettenger RB, Malekzadeh M, Marik JL, Struber M. Noncompliance with immunosuppressive medications in pediatric and adolescent patients receiving solid-organ transplants. *Transplantation* 2004; **77**: 778–782.
 - 17 Lewis J, Walker AS, Castro H *et al.* Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. *J Infect Dis* 2012; **205**: 548–556.
 - 18 The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. *Lancet Infect Dis* 2011; **11**: 273–283.
 - 19 Paton NI, Kityo C, Hoppe A *et al.* Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *N Engl J Med* 2014; **371**: 234–247.
 - 20 Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. *Antiviral Res* 2010; **85**: 59–74.
 - 21 Arathoon E, Schneider S, Baraldi E *et al.* Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naïve HIV-1-infected patients at week 96: ARTEMIS. *Int J STD AIDS* 2013; **24**: 12–17.
 - 22 Cain LE, Phillips A, Olson A *et al.* Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis* 2015; **60**: 1262–1268.
 - 23 Ramjan R, Calmy A, Vitoria M *et al.* Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. *Trop Med Int Health* 2014; **19**: 501–513.
 - 24 Wohl D, Oka S, Clumeck N *et al.* A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results. 15th European AIDS Conference; Barcelona 2015.
 - 25 Rijnders B, Stephan C, Lazzarin A *et al.* Switching from ritonavir or cobicistat boosted atazanavir (ATV) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): week 48 data in virologically suppressed adults. 15th European AIDS Conference; Barcelona 2015.
 - 26 Butler K. ART with weekends off is noninferior to continuous ART in young people on EFV+2NRTI. Conference on Retroviruses and Opportunistic Infections 2015; Washington, USA 2015.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Table S1. Number and proportion of participants developing virological failure, interrupting treatment, and developing TCVF, by risk group and age at the start of ART.

Table S2. Outcomes of TCVF, by risk group and age at the start of ART.

Appendix 1: authors/writing group (affiliation)

Ali Judd (AALPHI, CHIPS), Rebecca Lodwick (statistician), Antoni Noguera-Julian (CORISPE-cat), D. M. Gibb (CHIPS), Karina Butler (CHIPS), Dominique Costagliola (ANRS CO4 FHDH), Caroline Sabin (UK CHIC), Ard van Sighem (ATHENA), Bruno Ledergerber (SHCS), Carlo Torti (MODENA), Amanda Mocroft (EUROSIDA), Daniel Podzamczar (PISCIS), Maria Dorrucchi (CASCADE), Stéphane De Wit (St Pierre Cohort), Niels Obel (Danish HIV Cohort), François Dabis (ANRS CO3 AQUITAINE), Alessandro Cozzi-Lepri (ICONA), Federico García (Co-RIS), Norbert Brockmeyer (KOMPNET), Josiane Warszawski (ANRS CO1 EPF), Maribel Gonzalez-Tome (CORISPES-Madrid Cohort), Cristina Mussini (MODENA), Giota Touloumi (AMACS), Robert Zangerle (AHIVCOS), Jade Ghosn (ANRS CO6 PRIMO), Antonella Castagna (San Raffaele), Gerd Fätkenheuer (Cologne-Bonn), Christoph Stephan (FRANKFURT), Laurence Meyer (ANRS CO2 SEROCO), Maria Athena Campbell (Copenhagen RCC representative), Genevieve Chene (Bordeaux RCC representative) and Andrew Phillips (PLATO II project leader; UK CHIC).

Appendix 2: COHERE committees, coordinating centres, project leads and statisticians

Steering Committee - Contributing Cohorts: Robert Zangerle (AHIVCOS), Giota Touloumi (AMACS), Josiane Warszawski (ANRS CO1 EPF/ANRS CO11 OBSERVATOIRE EPF), Laurence Meyer (ANRS CO2 SEROCO), François Dabis (ANRS CO3 AQUITAINE), Murielle Mary Krause (ANRS CO4 FHDH), Jade Ghosn (ANRS CO6 PRIMO), Catherine Leport (ANRS CO8 COPILOTE), Linda Wittkop (ANRS CO13 HEPAVIH), Peter Reiss (ATHENA), Ferdinand Wit (ATHENA), Maria Prins (CASCADE), Heiner Bucher (CASCADE), Diana M. Gibb (CHIPS), Gerd Fätkenheuer (Cologne-Bonn), Julia del Amo (CoRIS), Niels Obel (Danish HIV Cohort), Claire Thorne (ECS), Amanda Mocroft (EuroSIDA), Ole Kirk (EuroSIDA), Christoph Stephan (Frankfurt), Santiago Pérez-Hoyos (GEMES-Haemo), Osamah Hamouda (German ClinSurv), Barbara Bartmeyer (German ClinSurv), Nikoloz Chkhartishvili (Georgian National HIV/AIDS), Antoni Noguera-Julian (CORISPEcat), Andrea Antinori (ICC), Antonella d'Arminio Monforte (ICONA), Norbert Brockmeyer (KOMPNET), Luis Prieto (Madrid PMTCT Cohort), Pablo Rojo (CORISPES-Madrid), Antoni Soriano-Arandes (NENEXP), Manuel Battegay (SHCS), Roger Kouyos (SHCS), Cristina Mussini (Modena Cohort), Pat Tookey (NSHPC), Jordi Casabona (PISCIS), José M. Miró (PISCIS), Antonella Castagna (San Raffaele), Deborah Konopnick (St. Pierre Cohort), Tessa Goetghebuer (St Pierre Paediatric Cohort), Anders Sönnberg (Swedish InfCare), Carlo Torti (MODENA), Caroline

Sabin (UK CHIC), Ramon Teira (VACH), Myriam Garrido (VACH) and David Haerry (European AIDS Treatment Group).

Executive Committee: Stéphane de Wit (Chair, St. Pierre University Hospital), Jose M^a Miró (PISCIS), Dominique Costagliola (FHDH), Antonella d'Arminio-Monforte (ICONA), Antonella Castagna (San Raffaele), Julia del Amo (CoRIS), Amanda Mocroft (EuroSida), Dorthe Raben (Head, Copenhagen Regional Coordinating Centre) and Geneviève Chêne (Head, Bordeaux Regional Coordinating Centre). Paediatric Cohort Representatives: Ali Judd and Pablo Rojo Conejo.

Regional Coordinating Centres: Bordeaux RCC: Diana Barger, Christine Schwimmer, Monique Termote and Linda Wittkop; Copenhagen RCC: Maria Campbell, Casper M. Frederiksen, Nina Friis-Møller, Jesper Kjaer, Dorthe Raben and Rikke Salbøl Brandt.

Project Leads and Statisticians: Juan Berenguer, Julia Bohlius, Vincent Bouteloup, Heiner Bucher, Alessandro Cozzi-Lepri, François Dabis, Antonella d'Arminio Monforte, Mary-Ann Davies, Julia del Amo, Maria Dorrucchi, David Dunn, Matthias Egger, Hansjakob Furrer, Marguerite Guiguet, Sophie Grabar, Ali Judd, Ole Kirk, Olivier Lambotte, Valérie Leroy, Sara Lodi, Sophie Matheron, Laurence Meyer, Jose M^a Miró, Amanda Mocroft, Susana Monge, Fumiyo Nakagawa, Roger Paredes, Andrew Phillips, Massimo Puoti, Michael Schomaker, Colette Smit, Jonathan Sterne, Rodolphe Thiebaut, Claire Thorne, Carlo Torti, Marc van der Valk, Linda Wittkop and Natasha Wyss.